One dose of an antibody drug protected from malaria infection during the malaria season in Mali, showing up to 88% effectiveness: demonstrating for the first time that a monoclonal antibody can prevent malaria in an endemic region.
BioNTech is set to take several mRNA candidates into clinical trials over the coming months: including vaccines for shingles, malaria and tuberculosis.
Lumen Bioscience says new data has been released demonstrating that its needle-free, spirulina-produced recombinant vaccinate protects against malaria.
Vir Biotechnology and the Bill & Melinda Gates Foundation have partnered up to develop broadly neutralizing antibodies designed to provide a ‘vaccinal effect’ for the treatment of HIV and prevention of malaria.
The World Health Organization is recommending widespread use of the RTS,S/AS01 (RTS,S) vaccine among children in sub-Saharan Africa and other regions with moderate to high malaria transmission.
BioNTech aims to develop the first mRNA-based malaria vaccine, hoping to reach clinical trials by 2022. Meanwhile, it is also exploring possibilities to set up mRNA manufacturing facilities on the African continent – which could potentially be used for...
A Phase 2b trial for the University of Oxford’s malaria vaccine candidate showed 77% efficacy in children, according to a study published in The Lancet. ‘We believe this vaccine could have a major public health impact’, say researchers.
Catalent has partnered with US non-profit PATH for antibody discovery using the CDMO’s GPEx cell line platform, funded by PATH’s Malaria Vaccine Initiative (MVI).
The new $50m facility will house 450 scientists in Rockville, Maryland to work across 12 vaccine development programmes, alongside the non-profit Biopreparedness organisation (BPO).
A recently opened facility will double production of Sanofi Pasteur’s vaccine Stamaril which could alleviate shortages in the wake of recent yellow fever outbreaks in parts of Africa.
Sanofi Pasteur says Mexican approval for Dengvaxia vindicates the ‘industrial risk’ it took when it invested €350m in a dengue fever vaccine plant in 2009.
Scientists trying to curb malaria deaths usually concentrate on preventing mosquito bites or developing human vaccines and therapies, but novel gene-editing tool CRISPR is opening up another path.
Takeda has taken a stake in Belgian bioprocessing start-up Univercells as part of a programme aimed at supplying low-cost vaccines to lower-income countries.
